Skip to content

Prime Medicine PRME Enterprise value

Enterprise value at other companies

Eli Lilly logo
Eli LillyLLY
$859.77B+10.6%
Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
$109.92B-9.5%
Intellia Therapeutics logo
Intellia TherapeuticsNTLA
$1.46B+100%
CRISPR Therapeutics logo
CRISPR TherapeuticsCRSP
$4.93B+69.8%
Beam Therapeutics logo
Beam TherapeuticsBEAM
$2.39B+51.2%
Regenxbio logo
RegenxbioRGNX
$488.35M+58.6%

Other financials

Income statement

See full
Revenue$838.0K-61.6%
Operating income-$50.7M+3.3%
Net income-$49.1M+5.3%
EPS (diluted)-$0.28+30.0%

Balance sheet

See full
Cash & equivalents$77.8M-26.6%
Total debt$114.5M-5.5%
Total equity$76.7M-28.3%
Total assets$294.7M-10.2%

Cash flow

See full
Operating cash flow-$42.7M+12.6%
CapEx$214.0K-91.2%
Free cash flow-$42.9M+16.3%

Valuation

See full
Market cap$574.36M+111%
P/S124×+6.3×

Profitability

See full
Operating margin-4,498.1%-1,134pp
Net margin-4,342.4%-1,099pp
FCF margin-3,607.4%

Returns & leverage

See full
Return on equity-216.1%+1,519pp
Debt / equity1.5×+0.4×
Current ratio3.8×-1.0×

Where this comes from

Calculated from Prime Medicine’s reported figures.

The official record: Prime Medicine’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Prime Medicine's enterprise value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Prime Medicine's enterprise value?
Prime Medicine (PRME) reported enterprise value of $665.04M in Q1 2026.
How has Prime Medicine's enterprise value changed year-over-year?
Prime Medicine's enterprise value increased by 140.8% year-over-year, from $276.22M to $665.04M.
What is the long-term trend for Prime Medicine's enterprise value?
Over 3 years (2022 to 2025), Prime Medicine's enterprise value has grown at a -18.0% compound annual growth rate (CAGR), from $1.21B to $666.08M.
What does enterprise value mean?
Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.